Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-12-01EMA Authorised: Rasagiline Viatris (previously Rasagiline Mylan) (rasagiline tartrate) — Viatris Limited
The EMA authorised Rasagiline Viatris (rasagiline tartrate) for Parkinson's disease, with Viatris Limited as the marketing authorisation hol…
-
FDA approval · 2025-11-10FDA Approved: ROPINIROLE — Original Application (Elite Laboratories, Inc.)
FDA approved Elite Laboratories, Inc.'s original application for a generic ropinirole product. The drug is indicated for Parkinson's disease…
-
FDA approval · 2025-10-10FDA Approved: ONGENTYS — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for ONGENTYS (opicapone) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2025-09-16FDA Approved: ROPINIROLE HYDROCHLORIDE — Supplemental Application (SOLCO HEALTHCARE US, LLC)
FDA approved a supplemental application for ropinirole hydrochloride from Solco Healthcare US, LLC, approving an additional generic version …
-
EMA approval · 2025-09-10EMA Authorised: Tasmar (tolcapone) — Viatris Healthcare Limited
The European Medicines Agency authorised Tasmar (tolcapone) by Viatris Healthcare Limited for the treatment of Parkinson disease.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-09-04FDA Approved: SELEGILINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for Selegiline Hydrochloride from Chartwell RX, LLC, enabling the generic product's approval.
-
FDA approval · 2025-08-01FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental ANDA for Pramipexole dihydrochloride by Macleods Pharmaceuticals Limited, enabling marketing of a generic pr…
-
EMA approval · 2025-07-17EMA Authorised: Nimvastid (rivastigmine) — Krka, d.d., Novo mesto
EMA authorised Nimvastid (rivastigmine) by Krka for treatment of dementia, including Alzheimer's disease and Parkinson's disease.
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HCL — Supplemental Application (Bionpharma Inc.)
FDA approves a supplemental application for amantadine hydrochloride submitted by Bionpharma Inc.
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for Amantadine Hydrochloride from Upsher-Smith Laboratories, authorizing a generic product with appr…
-
FDA approval · 2025-07-10FDA Approved: GOCOVRI — Supplemental Application (Adamas Pharma, LLC)
The FDA approved a supplemental application for GOCOVRI (amantadine) submitted by Adamas Pharma, LLC.
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (Strides Pharma Inc.)
FDA approves a supplemental application for Amantadine Hydrochloride submitted by Strides Pharma Inc., updating its approval scope under an …
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for Amantadine Hydrochloride by Zydus Lifesciences Limited.
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental ANDA for Amantadine Hydrochloride by Rising Pharma Holdings, Inc., enabling the marketing of the generic pro…
-
FDA approval · 2025-07-10FDA Approved: AMANTADINE HYDROCHLORIDE — Supplemental Application (BAJAJ MEDICAL, LLC)
FDA approved a supplemental application for Amantadine Hydrochloride from Bajaj Medical, LLC.
-
FDA approval · 2025-06-20FDA Approved: PRAMIPEXOLE DIHYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for pramipexole dihydrochloride from Alembic Pharmaceuticals Limited.
-
EMA approval · 2025-06-13EMA Authorised: Rivastigmine Actavis (rivastigmine hydrogen tartrate) — Actavis Group PTC ehf
EMA authorised Rivastigmine Actavis (rivastigmine hydrogen tartrate) for dementia-related indications including Alzheimer's disease and Park…
-
EMA approval · 2025-06-02EMA Authorised: Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) (levodopa;carbidopa;entacapone) — Orion Corporation
EU marketing authorisation granted for Corbilta, a fixed-dose combination of levodopa, carbidopa and entacapone, for Parkinson's disease, to…
-
EMA approval · 2025-05-07EMA Authorised: Ongentys (opicapone) — Bial - Portela Cª, S.A.
EMA authorised Ongentys (opicapone) by Bial - Portela Cª, S.A. for Parkinson disease.
-
FDA approval · 2025-05-05FDA Approved: RASAGILINE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's original application for rasagiline tablets (generic rasagiline) for use in Parkinson disease…
-
FDA approval · 2025-04-21FDA Approved: CABERGOLINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for cabergoline submitted by Mylan Pharmaceuticals Inc., confirming additional approval activity…
-
FDA approval · 2025-04-15FDA Approved: CARBIDOPA, LEVODOPA AND ENTACAPONE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the fixed-dose combination of carbidopa, levodopa, and entacapone as an original application for Macleods Pharmaceuticals Limit…
-
EMA approval · 2025-04-15EMA Authorised: Prometax (rivastigmine) — Almirall, S.A.
The EMA authorised Prometax (rivastigmine) for the treatment of Alzheimer's disease, Parkinson's disease, and dementia. The decision date is…
-
FDA approval · 2025-04-09FDA Approved: CARBIDOPA — Supplemental Application (Edenbridge Pharmaceuticals LLC.)
FDA approves a supplemental application for carbidopa from Edenbridge Pharmaceuticals LLC.
-
EMA approval · 2025-04-09EMA Authorised: Rasagiline ratiopharm (rasagiline) — Teva B.V.
EMA authorised Rasagiline ratiopharm (rasagiline) by Teva B.V. for the treatment of Parkinson's disease. It represents a generic entry for r…